Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ENDRA Life SciencesNDRA -0.62%19 3-Year EBITDA Growth Rate is 89.70% as of Jun. 2026, which is 8% above its 10-year median of 83.30. GuruFocus rates NDRA with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, ENDRA Life Sciences ranks better than 98.2% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 89.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 78.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of ENDRA Life Sciences was 89.70% per year. The lowest was 39.10% per year. And the median was 83.30% per year.
ENDRA Life Sciences (NAS:NDRA) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
ENDRA Life Sciences 3-Year EBITDA Growth Rate Related Terms
NDRA vs XWEL, MBAI, ISPC: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, ENDRA Life Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's 3-Year EBITDA Growth Rate falls into.
ENDRA Life Sciences 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 89.70% mean?
ENDRA Life Sciences (NDRA) has a 3-Year EBITDA Growth Rate of 89.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ENDRA Life Sciences and its competitors. This is near median its historical median of 83.30. Over the past decade, ENDRA Life Sciences' 3-Year EBITDA Growth Rate has ranged from 39.10 to 89.70. According to the industry distribution chart, ENDRA Life Sciences ranks #3 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 1.8%.
Is ENDRA Life Sciences' 3-Year EBITDA Growth Rate too high?
ENDRA Life Sciences' current 3-Year EBITDA Growth Rate of 89.70% is near median its 10-year median of 83.30. Over the past 10 years, this metric has ranged from a low of 39.10 to a high of 89.70. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 10.60. ENDRA Life Sciences' value of 89.70% is 746.2% above this industry median. Based on the distribution chart, ENDRA Life Sciences ranks #3 out of 167 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, ENDRA Life Sciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does ENDRA Life Sciences' 3-Year EBITDA Growth Rate compare to XWEL and MBAI?
According to the Medical Diagnostics & Research industry distribution chart, ENDRA Life Sciences ranks #3 out of 167 companies for 3-Year EBITDA Growth Rate. This places ENDRA Life Sciences in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.60. ENDRA Life Sciences' value of 89.70% is 746.2% above this benchmark. Historically, ENDRA Life Sciences' own 3-Year EBITDA Growth Rate has ranged from 39.10 to 89.70 over the past decade. While the company's 10-year median is 83.30 vs. the industry median of 10.60, ENDRA Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 10.60, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ENDRA Life Sciences's current 3-Year EBITDA Growth Rate of 89.70% is 746.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ENDRA Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 10.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ENDRA Life Sciences's current 3-Year EBITDA Growth Rate is 89.70%, which is near median its own 10-year median of 83.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENDRA Life Sciences stock overvalued right now?
ENDRA Life Sciences (NDRA) has a current 3-Year EBITDA Growth Rate of 89.70%. The current 3-Year EBITDA Growth Rate is 89.70%, which is near median its 10-year median of 83.30 and 746.2% above the Medical Diagnostics & Research industry median of 10.60. ENDRA Life Sciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For ENDRA Life Sciences (NDRA), the current 3-Year EBITDA Growth Rate is 89.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
19GF Score
Get the complete analysis for NDRA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NDRA has been successfully added to your 
